Despite the unprecedented efficacy of the PD‐L1/PD‐1 blockade in cancer immunotherapies, only a small proportion of patients with PD‐L1‐positive tumors achieve a high objective response rate, while others seem to develop resistance to such therapy. The gene discussed is CD274; the disease is cancer.